Workshop with a Focus on drug development by Novo Repair Impact Fund
Introduction, by Ursula Theuretzbacher, Center for Anti-Infective Agents, Vienna, Austria
Putting the puzzle pieces together by Enza Di Modugno, Global Head Infectious Disease and Immunology, Pharma Partnering, F. Hoffmann-La-Roche Ltd, Basel, Switzerland
Chemistry, production, stability by Aleksandar Danilovsky, Chief Scientific Officer (CSO), Xellia Pharmaceuticals, Copenhagen, Denmark
Discussion
13:00 – 21:30
Registration, poster presentations and exhibition open
13:00 – 14:00
Lunch Break
14:00 – 15:30
Opening | Keynote | Plenary talk
AMR innovation: Finally on track to market & patients?
Intro talks by:
Marc Gitzinger, Vice-Président, BEAM Alliance & CEO Bioversys
Martin Heidecker, AMR Action Fund
Aleksandra Opalska, European Commission
Moderator:
Marc Gitzinger, Vice-Président, BEAM Alliance & CEO Bioversys
Speakers:
Erin Duffy, CARB-X
William Stubbings, Roche
Valeria Gigante, WHO
Bruce Altevogt, EFPIA
15:30 – 16:00
Coffee Break with poster session & exhibition
15:30 – 20:30
1-to-1 Partnering Meetings
16:00 – 17:30
Parallel Tracks
A new era for TB drug development: From innovation trial design to efficient drug regiments
Moderator:
Michel Pieren, BioVersys
Speakers:
Andreas Diacon, TASK
Michael Hoelscher, University of Munich
David Barros-Aguirre, GSK
Hosted by the IMI AMR Accelerator & in cooperation with the Unite4TB/Era4TB consortia
Diagnostics in AMR: Focus on market needs & learnings from COVID-19 innovations
Moderator:
Till Bachmann, University of Edinburgh
Speakers:
Stefanie Deinhard-Emmer, University Clinic of Jena
Jessica Caffrey, QuantumDx
Cecilia Ferreyra, FIND
Impact of pull incentives on the R&D portfolio: Current status & perspectives
Moderator:
Kevin Outterson, Professor of Law & N. Neal Pike Scholar in Health and Disability Law, Boston University & Executive Director, CARB-X
Registration, poster presentations and exhibition open
08:30 – 10:00
Parallel Tracks
Animal infection models & other tools for preclinical efficacy
Moderator:
Peter Jackson, INFEX Therapeutics
Speakers:
Jennifer Hoover, GSK
Glenn Dale, BioVersys
Erin Duffy, CARB-X
Robin Duman, Vibiosphen
in cooperation with IMI AMR Accelerator & further partners
Novel Technologies to combat AMR (AI, phages, imaging, metabolomics, microfluids)
Moderator:
Christoph Dehio, NCCR AntiResist
Speakers:
Jon Stokes, PhareBio
Martin Loessner, ETH Zurich
Knut Drescher, Uni Basel
Mattia Zampieri, ETH ZUrich
Sundar Hengoju, Leibniz HKI
in cooperation with the NCCR AntiResist network
Focus on One Health
Moderator:
Lesley Ogilvie, Global AMR R&D Hub
Speakers:
Tine Rikke Jorgenson, WHO
Jomana Musmar, PACCARB
Ghada Zoubiane, ICARS
Amit Khurana, CSE
hosted by the Global AMR R&D Hub
10:00 – 10:45
Coffee Break with poster session & exhibition
10:00 – 16:30
1-to-1 Partnering Meetings
10:45 – 12:00
Plenary Session
From One Health to Sustainable Development Goals: Why there is no option than to fight AMR on a global scale
Moderator:
Peter Beyer, WHO
Speakers:
Louise Norton-Smith, Department of Health & Social Care, UK
Jomana Musmar, PACCARB, US government
Jean-Pierre Paccaud , GARDP
Emma Hannay, FIND
12:00 – 13:30
Lunch Break with poster session & exhibition
and
UK Government hosted lunch reception with HMA Jane Owen Due to unforeseen circumstances, Dame Sally Davies, UK Special Envoy on AMR will not be attending the AMR Conference in Basel. Her Majesty’s Ambassador to Switzerland, Jane Owen will be attending on behalf of the UK Government.
13:30 – 14:30
Parallel Tracks
Focus on clinical development/trials & regulatory perspectives
Moderator:
Florence Séjourné, Da Volterra
Speakers:
Marc Bonten, Utrecht University/ECRAID
Najy Alsayed, Menarini
Radu Botgros, EMA
William Stubbings, Roche
Vaccines back on track to combat AMR: New approaches & challenges
Moderator:
Bernhard Kerscher, PEI
Speakers:
Isabel Frost, WHO
Cristina Alaimo, LimmaTech Biologics AG
Juanjo Infante, VAXDYN
Diagnostic programmes
Moderator:
Till Bachmann, University of Edinburgh
Speakers:
Anita Suresh, FINDDx
Belinda Ngongo, Illumina
Christian Brandt, Nanozoo
in cooperation with
14:30 – 15:00
Networking Break
15:00 – 16:00
Parallel Tracks
Focus on clinical needs: Which innovation in AMR is in demand?
Moderator:
Valeria Gigante, WHO
Speakers:
Apostolos Armaganidis, Attikon University Hospital
Andreas Widmer, University Hospital Basel
Cecilia Ferreyra, FINDDx
in cooperation with WHO
Therapeutic programmes
Moderator:
Frédéric Peyrane, BEAM Alliance
Speakers:
Glenn Dale, BioVersys
Peter Jackson, Infex Therapeutics
Florence Séjourné, Da Volterra
Georges Gaudriault, Deinove
Cindy Fevre, Pherecydes
(company presentations)
Focus on fungal infections: Current trends & developments – (shared lessons learned for AMR?)
Moderator:
Mark Jones, Basilea
Speakers:
Maja Weisser Rohacek, Uni Basel
Rienk Pypstra, Pfizer
Hatim Sati, WHO
16:00 – 16:30
Coffee Break with poster session & exhibition
16:30 – 17:30
Plenary session
Cooperation as new normal? New cooperation models (PPPs, investors, Pharma/SMEs, public entities) – from early stage to clinical development
Moderator:
Marc Lemonnier, Antabio & BEAM Alliance
Speakers:
Erin Duffy, CARB-X
Sebastian Kreuz, Boehringer Ingelheim
Jürgen Popp, Leibniz Institute of Photonic Technology